Drug intelligence / Profile preview

JY-09

Development stage: Phase 3
Lead developer: Beijing Dongfang Biotech
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

JY-09 is a recombinant fusion protein that acts as a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is constructed by fusing Exendin-4, a GLP-1 receptor agonist, with the Fc fragment of human Immunoglobulin G2 (IgG2). This design extends its half-life and allows for less frequent dosing. JY-09 is being developed primarily for the treatment of type 2 diabetes mellitus, where it improves glycemic control by enhancing insulin secretion in response to elevated blood glucose levels and suppressing appetite. The originator and main developer is Beijing Dongfang Biotech.

Other names: Exendin-4Fc fusion proteinExendin4Fc fusion proteinExendin 4Fc fusion protein

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on JY-09.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JY-09.

Explore the full profile